Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ARCT
FechaHoraFuenteTítuloSímboloCompañía
15/05/202415:01Business WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/05/202415:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/05/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/05/202415:01Business WireArcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
25/04/202415:01Business WireArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/03/202415:01Business WireArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/02/202408:00Business WireArcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
22/02/202407:30Business WireArcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
20/02/202408:00Business WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/02/202407:30PR Newswire (US)New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
21/12/202307:00Business WireCSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
21/12/202307:00PR Newswire (US)CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/12/202319:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
04/12/202307:30Business WireArcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
28/11/202307:05PR Newswire (US)Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
28/11/202307:00Business WireJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in AdultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
27/11/202308:13Dow Jones NewsArcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
27/11/202307:30Business WireArcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
15/11/202307:51IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/11/202315:01Business WireArcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
25/10/202315:01Business WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
04/10/202307:30Business WireArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese GovernmentNASDAQ:ARCTArcturus Therapeutics Holdings Inc
26/09/202307:30Business WireArcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
19/09/202307:30Business WireStudy Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 VariantsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/09/202307:30Business WireArcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19NASDAQ:ARCTArcturus Therapeutics Holdings Inc
17/08/202307:30Business WireArcturus Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
14/08/202308:00Business WireArcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese GovernmentNASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/08/202315:20Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/08/202315:01Business WireArcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
24/07/202315:01Business WireArcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ARCT